DEA Publishes Schedule III Proposed Rule for Cannabis — What It Actually Means
The Drug Enforcement Administration published its proposed rule to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act on Tuesday, initiating the most consequential federal cannabis regulatory action in over 50 years. The 168-page document, published in the Federal Register, opens a 60-day public comment period and sets the stage for a final rule that could take effect by late 2026 or early 2027.
The proposed rule follows the Department of Health and Human Services recommendation made in August 2023 and the executive order that accelerated the review process. Its publication is historic — but understanding what Schedule III classification actually changes (and what it doesn’t) requires reading past the headlines.
What Schedule III Means
Schedule III classification places cannabis alongside drugs like ketamine, anabolic steroids, and Tylenol with codeine. These substances are considered to have moderate-to-low potential for dependence and are available through prescription with accepted medical use.
For cannabis, the practical implications fall into three categories: tax relief, research access, and legal status.
Tax relief (the big one): The Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses. This provision has been devastating for cannabis companies, effectively taxing them on gross revenue rather than net income. A typical cannabis business pays an effective federal tax rate of 60-80% under 280E, compared to 21% for a normal corporation.
Schedule III classification would eliminate 280E’s application to cannabis businesses immediately upon taking effect. The financial impact is enormous. Industry estimates suggest 280E costs cannabis companies $2-3 billion annually in excess taxes. Its elimination would be the single largest financial event in the legal cannabis industry’s history, immediately improving profitability across every licensed operator in the country.
Research access: Schedule I classification requires researchers to obtain special DEA licenses to study cannabis, creating bureaucratic barriers that have severely limited clinical research. Schedule III would dramatically simplify the research approval process, placing cannabis research on par with other prescription drug studies. The DEA testing lab backlog that has hampered research would also be alleviated under the streamlined framework.
Legal status: This is where the nuance matters. Schedule III classification does not legalize cannabis. It does not create a federal regulatory framework for recreational use. It does not enable interstate commerce. It does not override state laws. Cannabis would remain a controlled substance requiring a prescription for legal access under federal law.
The disconnect between Schedule III federal status and state recreational programs creates a legal gray area. States would continue operating their recreational markets as they do now — technically in violation of federal law but protected by enforcement discretion and the appropriations riders that prohibit DOJ from using funds to interfere with state programs.
What the Proposed Rule Contains
The DEA’s proposed rule addresses several key implementation questions.
Prescriptive access: Under Schedule III, cannabis could theoretically be prescribed by physicians and dispensed through pharmacies. The proposed rule acknowledges this possibility but defers to FDA guidance on whether and how cannabis products might enter the pharmaceutical distribution chain. In practice, the existing state dispensary infrastructure would continue operating, with pharmaceutical cannabis representing a separate (and much smaller) market segment.
Manufacturing and distribution: The proposed rule would subject cannabis manufacturers to DEA registration requirements applicable to Schedule III substances. However, it includes a transitional provision recognizing state-licensed operators, allowing them to continue operations while the federal registration framework is developed.
Import/export: Schedule III classification would enable the legal importation of cannabis products for medical and research purposes under DEA-issued permits. This has significant implications for Canadian cannabis exporters and could eventually create a pathway for international cannabis trade involving U.S. companies.
Industry Reaction
The cannabis industry’s response has been overwhelmingly positive, focused almost entirely on the 280E elimination. Stock prices for the major MSOs jumped 15-25% on the announcement, with Curaleaf, Trulieve, Green Thumb, Verano, and Cresco Labs all seeing significant gains.
Industry trade groups praised the action while emphasizing that rescheduling is an incremental step rather than a complete solution. The National Cannabis Industry Association called the proposed rule “a long-overdue recognition of scientific reality” while reiterating its position that full descheduling and comprehensive federal regulation remain the ultimate policy goals.
Advocates for legalization were more measured. The Drug Policy Alliance noted that Schedule III classification “changes the tax code but not the criminal code” and expressed concern that rescheduling could reduce political urgency for full legalization by addressing the industry’s most pressing financial concern without resolving the fundamental legal contradictions.
What Happens Next
The 60-day comment period will generate significant public input. Industry groups, medical organizations, law enforcement agencies, and advocacy organizations will all submit comments that the DEA must review and address before publishing a final rule.
Legal challenges are expected regardless of the final rule’s content. At least two organizations have indicated they will challenge rescheduling on administrative law grounds, arguing that the DEA’s process did not adequately consider the scientific evidence or that Schedule III is the wrong classification (with some arguing for Schedule II and others for full descheduling).
The timeline for a final rule is uncertain but most analysts expect publication between October 2026 and March 2027, with an effective date 30-60 days after publication. If legal challenges result in injunctions, the timeline could extend significantly.
For the cannabis industry, the proposed rule represents the closest the federal government has come to meaningful reform since prohibition began. Whether it leads to a final rule — and whether that rule survives legal challenge — will determine the trajectory of the entire industry for the next decade.